Table 3.

Univariate and multivariate logistic regression analyses of factors associated with CR achievement after AHSCT.

Variable		Univariate				Multivariate
		OR	95%CI Lower	95%CI Upper	p	OR	95%CI Lower	95%CI Upper	p
CR before AHSCT		23.10	2.53	210.89	0.0054	38.55	3.04	489.24	0.0048
≥2 lines before AHSCT		0.31	0.07	1.27	0.1027
Cytogenetic risk group	Unknown	Reference
	Standard Risk	0.21	0.02	1.90	0.1662
	High Risk	1.71	0.22	13.56	0.6094
Maintenance treatment		0.65	0.06	6.72	0.7145
Melphalan dose	Mel 200	0.60	0.18	2.01	0.4028
	Reduced dose	Reference
Induction regimen	Bortezomib-based	2.89	0.69	12.02	0.1448
ISS	I/II	Reference
	III	0.25	0.06	1.06	0.0596
Age	<60	Reference
	>60	0.49	0.15	1.63	0.2438
Paraprotein type	Other	Reference
	LCD	1.00	0.22	4.61	1.0000
hsa-miR-221-3p T1		2.97	0.83	10.59	0.0926
hsa-miR-15b-5p T1		0.78	0.36	1.70	0.5329
hsa-miR-223-3p T1		5.76	1.63	20.28	0.0065	4.72	1.14	19.59	0.0327
hsa-miR-320c T1		0.73	0.26	2.10	0.5647
hsa-miR-361-3p T1		0.82	0.29	2.27	0.6954
hsa-miR-150-5p T1		1.37	0.63	2.98	0.4222
hsa-miR-221-3p T2		3.57	1.09	11.75	0.0362	3.29	0.61	17.76	0.1659
hsa-miR-15b-5p T2		1.18	0.51	2.73	0.6936
hsa-miR-223-3p T2		1.70	0.84	3.44	0.1390
hsa-miR-320c T2		0.76	0.37	1.58	0.4628
hsa-miR-361-3p T2		1.30	0.75	2.26	0.3432
hsa-miR-150-5p T2		0.92	0.48	1.73	0.7903